The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to GSK5764227 (GSK’227) for the treatment of adult patients with relapsed or refractory (R/R) osteosarcoma who have ...
through the use of differentiated mechanisms of actions including antibody-drug conjugates, antibodies and proteins. We focus on advancing therapies that leverage our core strengths in ...
Korea Joongang Daily on MSN8h
Ulcerative colitis drug Zymfentra to generate fifth of Celltrion's 2025 revenueCelltrion plans to generate 20 percent of its annual revenue this year from its original drug Zymfentra as part of its ...
Axcynsis Therapeutics Pte Ltd ("Axcynsis"), a privately held biopharmaceutical company specialized in delivering Antibody ...
Pfizer is expanding its collaboration with the start-up PostEra, which applies artificial intelligence to medicinal chemistry ...
Roche has licensed an antibody-drug conjugate (ADC) designed to treat advanced small-cell lung cancer from China-based Innovent Biologics for $80 million up front and up to $1 billion in milestone ...
A panelist discusses how loncastuximab tesirine, an antibody-drug conjugate targeting CD19, shows promise in combination with ...
GSK5764227 (HS-20093) is a novel antibody-drug conjugate composed of a fully human anti-B7-H3 monoclonal antibody covalently linked to a topoisomerase inhibitor payload.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback